12:00 AM
 | 
Sep 16, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Actos pioglitazone: Phase III started

Takeda and Zinfandel Pharmaceuticals Inc. (Durham, N.C.) began the double-blind, international Phase III TOMMORROW trial of oral AD-4833 once daily for up to 5 years and the biomarker risk assignment algorithm in about 5,800 cognitively normal subjects ages 65-83. Subjects who are assessed as low risk by the biomarker risk assignment algorithm will receive placebo while those assessed...

Read the full 286 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >